Literature DB >> 10582680

Gender differences in p53 mutational status in small cell lung cancer.

J E Tseng1, M Rodriguez, J Ro, D Liu, W K Hong, L Mao.   

Abstract

Mutations in the p53 tumor suppressor gene have been demonstrated to be one of the most frequent genetic abnormalities in human cancers. Previous studies have shown that the frequency of p53 mutations is significantly higher in small cell lung cancer than in non-small cell lung cancer. However, this conclusion was based in large part on data derived from tumor cell lines and from studies with relatively small sample sizes and biased gender populations. To determine the mutational frequency in the p53 tumor suppressor gene and a potential difference in gender, we analyzed primary small cell lung cancer tumors from 65 patients (37 males and 28 females) for p53 mutations between exons 5 and 9. Mutations were found in 37 of 65 tumors (57%) within the region of p53 analyzed. Interestingly, none of the tumors from females contained more than one mutation, whereas four of the tumors from males contained more than one mutation. The most common mutation in this population was an adenosine-to-guanine transition (27%), followed by guanine-to-thymidine transversion (17%) and guanine-to-adenosine transition (12%). The gender difference in p53 mutational rate identified in this study suggests that a higher proportion of female tumors may develop through pathways not involving p53 mutations.

Entities:  

Mesh:

Year:  1999        PMID: 10582680

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Mutant p53 cooperates with ETS2 to promote etoposide resistance.

Authors:  Phi M Do; Lakshman Varanasi; Songqing Fan; Chunyang Li; Iwona Kubacka; Virginia Newman; Krishna Chauhan; Silvano Rakeem Daniels; Maurizio Boccetta; Michael R Garrett; Runzhao Li; Luis A Martinez
Journal:  Genes Dev       Date:  2012-04-15       Impact factor: 11.361

2.  A novel anti-c-Kit antibody-drug conjugate to treat wild-type and activating-mutant c-Kit-positive tumors.

Authors:  Jin-Ock Kim; Kwang-Hyeok Kim; Eun Ji Baek; Bomi Park; Min Kyung So; Byoung Joon Ko; Han-Jik Ko; Sang Gyu Park
Journal:  Mol Oncol       Date:  2021-08-29       Impact factor: 6.603

3.  Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis.

Authors:  Eun-Woo Lee; Min-Sik Lee; Suzanne Camus; Jaewang Ghim; Mi-Ran Yang; Wonkyung Oh; Nam-Chul Ha; David P Lane; Jaewhan Song
Journal:  EMBO J       Date:  2009-06-18       Impact factor: 11.598

Review 4.  Clinical implication of p53 mutation in lung cancer.

Authors:  Barbara G Campling; Wafik S El-Deiry
Journal:  Mol Biotechnol       Date:  2003-06       Impact factor: 2.695

Review 5.  Lung cancer in never smokers: molecular profiles and therapeutic implications.

Authors:  Charles M Rudin; Erika Avila-Tang; Curtis C Harris; James G Herman; Fred R Hirsch; William Pao; Ann G Schwartz; Kirsi H Vahakangas; Jonathan M Samet
Journal:  Clin Cancer Res       Date:  2009-09-15       Impact factor: 12.531

6.  Validating a targeted next-generation sequencing assay and profiling somatic variants in Chinese non-small cell lung cancer patients.

Authors:  Ruirui Jiang; Bo Zhang; Xiaodong Teng; Peizhen Hu; Sanpeng Xu; Zuyu Zheng; Rui Liu; Tingdong Tang; Feng Ye
Journal:  Sci Rep       Date:  2020-02-07       Impact factor: 4.379

7.  Metabolomic profiling of dried blood spots reveals gender-specific discriminant models for the diagnosis of small cell lung cancer.

Authors:  Li Yu; Kefeng Li; Xiangmin Li; Chao Guan; Tingting Sun; Xiaoye Zhang
Journal:  Aging (Albany NY)       Date:  2020-01-12       Impact factor: 5.682

8.  Mutation Analysis of TP53 Tumor Suppressor Gene in Colorectal Cancer in Patients from Iran (Kerman Province).

Authors:  Azadeh Lohrasbi Nejad; Mohammad Mehdi Yaghoobi
Journal:  Iran J Basic Med Sci       Date:  2012-01       Impact factor: 2.699

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.